Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H16N2O5 |
| Molecular Weight | 256.2551 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O
InChI
InChIKey=XACKNLSZYYIACO-DJLDLDEBSA-N
InChI=1S/C11H16N2O5/c1-2-6-4-13(11(17)12-10(6)16)9-3-7(15)8(5-14)18-9/h4,7-9,14-15H,2-3,5H2,1H3,(H,12,16,17)/t7-,8+,9+/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antiviral activity of 2,3'-anhydro and related pyrimidine nucleosides against hepatitis B virus. | 2010-11-15 |
|
| 3D-QSAR studies on antitubercular thymidine monophosphate kinase inhibitors based on different alignment methods. | 2006-02-15 |
|
| Synthesis and in vitro anti-mycobacterial activity of 5-substituted pyrimidine nucleosides. | 2005-12-15 |
|
| Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors. | 2003-10-21 |
|
| Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. | 2003-09-15 |
|
| Comparative study of purine and pyrimidine nucleoside analogues acting on the thymidylate kinases of Mycobacterium tuberculosis and of humans. | 2003-08-04 |
|
| Synthesis and antiviral activity of novel 5-(1-cyanamido-2-haloethyl) and 5-(1-hydroxy(or methoxy)-2-azidoethyl) analogues of uracil nucleosides. | 2001-10-11 |
|
| Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. | 2001-04 |
|
| Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes. | 2000-10-15 |
|
| Structure-activity relationship of the affinity of 5-substituted uracil nucleoside analogues for varicella-zoster virus thymidine kinase and their activity against varicella-zoster virus. | 1997-08 |
|
| Synthesis of new acyclic pyrimidine nucleoside analogs as potential antiviral drugs. | 1994-09-16 |
|
| Synthesis and antiviral activity of novel 5-(1-azido-2-haloethyl) and 5-(1-azido-, amino-, or methoxyethyl) analogs of 2'-deoxyuridine. | 1993-08-20 |
|
| Synthesis and antiviral activity of phosphonoacetic and phosphonoformic acid esters of 5-bromo-2'-deoxyuridine and related pyrimidine nucleosides and acyclonucleosides. | 1989-02 |
|
| Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. | 1988-12-01 |
|
| Synthesis and antitumor and antiviral properties of 5-alkyl-2'-deoxyuridines, 3',5'-cyclic monophosphates, and neutral cyclic triesters. | 1986-04 |
|
| Comparison of susceptibilities of varicella-zoster virus and herpes simplex viruses to nucleoside analogs. | 1986-03 |
|
| Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2. | 1986-01 |
|
| Synthesis and antiviral activity of the carbocyclic analogues of 5-ethyl-2'-deoxyuridine and of 5-ethynyl-2'-deoxyuridine. | 1986-01 |
|
| Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus. | 1985-08 |
|
| 5-substituted deoxyuridines--structural requirements for antiviral activity against herpes simplex virus types 1 and 2 and possible biochemical basis for relative potency. | 1984-06 |
|
| Antiherpes activity of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil and some other 5-substituted uracil arabinosyl nucleosides in two different cell lines. | 1983-09 |
|
| Susceptibility of recent clinical isolates of herpes simplex virus to 5-ethyl-2'-deoxyuridine: preferential inhibition of herpes simplex virus type 2. | 1983-05 |
|
| In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. | 1982-01 |
|
| The 5'-monophosphates of 5-propyl- and 5-ethyl-2'-deoxyuridine do not inhibit the replication of deoxythymidine kinase deficient (TK-) mutants of herpes simplex virus. | 1980-10-15 |
|
| Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2. | 1980-04 |
|
| Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice. | 1979-11 |
|
| In vitro antiherpesviral activity of 5-alkyl derivatives of 1-beta-D-arabinofuranosyluracil. | 1979-08 |
|
| (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. | 1979-06 |
|
| Effect of treatment with 5-ethyl-2'-deoxyuridine on herpes simplex virus encephalitis in normal and immunosuppressed mice. | 1978-11 |
|
| 5-Propyl-2'-deoxyuridine: a specific anti-herpes agent. | 1978-03 |
|
| Antiviral action and cellular toxicity of four thymidine analogues: 5-ethyl-,5-vinyl-, 5-propyl-, and 5-allyl-2'- deoxyuridine. | 1976-07 |
|
| Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. | 1976-03 |
|
| 13-Alkylpyrimidine nucleosides. Preparation and properties of 5-ethyl-2'-deoxycytidine and related nucleosides. | 1974-03 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1894930
topical edoxudine 3.0% cream
Route of Administration:
Topical
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QD06BB09
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
||
|
WHO-ATC |
D06BB09
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
||
|
NCI_THESAURUS |
C29575
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15176-29-1
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
100000080512
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL318153
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
SUB06460MIG
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
m4833
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | Merck Index | ||
|
66377
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
758405
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
DTXSID4045890
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
49428
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | RxNorm | ||
|
C87662
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
15ZQM81Y3R
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
C022811
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
239-226-1
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
DB13421
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
5512
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
3173
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
EDOXUDINE
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY | |||
|
U-62
Created by
admin on Mon Mar 31 17:56:02 GMT 2025 , Edited by admin on Mon Mar 31 17:56:02 GMT 2025
|
PRIMARY |
ACTIVE MOIETY